Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

20.71
-0.6200-2.91%
Post-market: 20.50-0.2100-1.01%19:49 EDT
Volume:2.03M
Turnover:42.45M
Market Cap:2.86B
PE:-18.19
High:21.65
Open:21.42
Low:20.45
Close:21.33
52wk High:27.34
52wk Low:9.57
Shares:138.26M
Float Shares:118.91M
Volume Ratio:0.84
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1384
EPS(LYR):-5.0048
ROE:-37.11%
ROA:-5.96%
PB:5.48
PE(LYR):-4.14

Loading ...

Arrowhead Pharmaceuticals Earns $100 Million Milestone From Sarepta Therapeutics

THOMSON REUTERS
·
Jul 28

Arrowhead Pharmaceuticals Inc - Expects $200 Mln Milestone by End of 2025

THOMSON REUTERS
·
Jul 28

Arrowhead Pharmaceuticals Announces Inducement Grants for 38 New Employees Under NASDAQ Rule 5635(c)(4)

Reuters
·
Jul 25

Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jul 25

Arrowhead Pharmaceuticals Shares up 2% After Co Still Expects Milestone Payments From Sarepta Therapeutics

THOMSON REUTERS
·
Jul 23

Arrowhead Pharmaceuticals Shares up 1.6% Premarket

THOMSON REUTERS
·
Jul 23

Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks

Reuters
·
Jul 23

Arrowhead issues statement on exclusive license agreement with Sarepta

TIPRANKS
·
Jul 23

BRIEF-Arrowhead Pharmaceuticals Issues Statement On Status Of Ongoing Agreement With Sarepta Therapeutics

Reuters
·
Jul 23

BRIEF-Arrowhead Expects Sarepta To Meet Financial Obligations Under License Agreement

Reuters
·
Jul 23

Arrowhead Pharmaceuticals Issues Statement on the Status of Its Ongoing Agreement With Sarepta Therapeutics

THOMSON REUTERS
·
Jul 23

Arrowhead Pharmaceuticals: IF Sarepta Fails to Make $100 Mln or $200 Mln Near-Term Patient Enrollment Payment, Co Will Have Right to Terminate Agreement

THOMSON REUTERS
·
Jul 23

Arrowhead Pharmaceuticals: Expects Sarepta to Continue to Meet Required Financial Obligations Under License and Collaboration Agreement

THOMSON REUTERS
·
Jul 23

Arrowhead Pharmaceuticals to Announce Fiscal 2025 Third Quarter Financial Results

Reuters
·
Jul 22

BUZZ-Arrowhead Pharma tumbles on Sarepta partnership payment fears after safety crisis

Reuters
·
Jul 22

Arrowhead falls -8.9%

TIPRANKS
·
Jul 21

UBS downgrades Arrowhead Pharmaceuticals (ARWR) to a Hold

TIPRANKS
·
Jul 21

Cautious Hold Rating on Arrowhead Pharmaceuticals Amid Uncertainty in Sarepta Partnership

TIPRANKS
·
Jul 21

Insiders At Arrowhead Pharmaceuticals Sold US$3.1m In Stock, Alluding To Potential Weakness

Simply Wall St.
·
Jul 18

Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management

TIPRANKS
·
Jul 12